期刊文献+

抗菌药物的使用方法与超广谱β-内酰胺酶控制之间的关系

Association of Antibiotic Utilization Measures with Control of Extended-spectrum β-1actamases
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:探讨哌拉西林/他唑巴坦对减少产超广谱β-内酰胺酶(ESBL)大肠埃希菌或肺炎克雷伯菌定植的价值。方法:研究分为3个月的第Ⅰ阶段(干预前阶段)和6个月的第Ⅱ阶段(干预阶段),在干预前阶段,所有患者均按常规应用抗菌药物治疗各种感染。第Ⅱ阶段前3个月开始抗菌药物干预,所有感染患者推荐用哌拉西林/他唑巴坦治疗(替代3代头孢至少50.0%)。通过直肠拭子培养检查,用双纸片扩散法测定干预前阶段和干预后阶段(最后3个月)患者是否产ESBL的大肠埃希菌或肺炎克雷伯菌。结果:(1)总体上产ESBL的大肠埃希菌或肺炎克雷伯菌的获得率在干预前后从20.0%降至17.0%,但差异无统计学意义。(2)在社区产ESBL的大肠埃希菌或肺炎克雷伯菌呈高的获得率。结论:医院内干预前后产ESBL大肠埃希菌或肺炎克雷伯菌的获得率差异无统计学意义。 Objective:To determine the acquisition rate of ESBL-producing E. coli or K. pneumoniae, both pre- and post-intervention.To determine the value of using piperacillin/ tazobactam in reducing the cases of ESBL-producing E. coli or K. pneumoniae colonization and infection. Methods:The total duration of the study was 9 months. All patients admitted or transferred to the respiratory unit will be enrolled. This study had 3-month Phase Ⅰ (pre-intervention phase) period and 6-month Phase Ⅱ (intervention phase) period. In Pre-intervention Phase, Routine procedure for respiratory units was performed and the standard prescribed antibiotic was given to the patients with infection. After Intervention Period (First 3 Months), Routine medical procedures were done. Piperacillin/tazobactam was the primary antibiotic used ( at least 50% replacement of ceftazidime ) . Patient underwent rectal swab for detection of ESBL and non-ESBL pathogens by double-disc diffusion within 48 hours before or after admission or discharge from the respiratory unit. Result: (1)However, the acquisition rate of ESBL-producing E. coli and K. Pneumoniae has only decreased from 20% to 17% with no significant statistical difference between preintervention and post- intervention. (2)h is apparent that the acquisition rate of ESBL-producing E. coli or K. pneumoniae was higher in community. Conelusiion: The aequisiton rate of ESBL-Producing E. Colin and K. Pneumoniae has no significant statisbical difference between-phase differences.
作者 冯健 倪松石 吕学东 贵素琴 褚少朋 FENG Jian, NI Songshi, LV Xuedong, BEN Suqin,CHU Shaopeng~ (Department of Respiration; ~Departement of Laboratory Medicine, Affiliated Hospital of Nantong University, Jiangsu 226001 )
出处 《交通医学》 2008年第4期 369-370,377,共3页 Medical Journal of Communications
关键词 超广谱β-内酰胺酰 抗菌药物干预 直肠拭子培养 extended-spectrum β-lactamases Antibiotic Intervention Rectal swab
  • 相关文献

参考文献11

  • 1Knothe H, Shah P, Kremery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens[J]. Infection, 1983,11 (6):315-317. 被引量:1
  • 2Romero L, Lopez L, Rodriguez-Bano J, et al. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases[J]. Clin Microbiol Infect, 2005,11 (8):625-631. 被引量:1
  • 3Giamarellou H. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases(ESBLs) [J]. Clin Microbiol Infect, 2005,11 (Suppl 4) : 1-16. 被引量:1
  • 4Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase- producing organisms[J]. Int J Antimicrob Agents,2005,26(2): 114-119. 被引量:1
  • 5Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-produeing Klebsiella pneumoniae baeteraemia with earbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates [J]. J Antimierob Chemother,2006,58 (5):1074-1077. 被引量:1
  • 6Daley D, Mulgrave L, Munro R, et al. An evaluation of the in vitro activity of piperacillin/tazobactam[J].Pathology, 1996,28 (2):167-172. 被引量:1
  • 7Bagattini M, Crivaro V, Di Popolo A, et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit[J]. J Antimicrob Chemother, 2006,57(5):979-982. 被引量:1
  • 8Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002)[J]. Ann Clin Microbiol Antimicrob, 2004,3:14. 被引量:1
  • 9Pena C, Gudiol C, Tubau F, et al.Risk-factors for acquisition of extended-spectrum beta-lactamaase-producing Escherichia coli among hospitalised patients [J].Clin Microbiol Infect, 2006,12(3):279-284. 被引量:1
  • 10周庆涛,姚婉贞,陈亚红,沈宁,伍蕊,刘振英.2001-2005年呼吸科病房临床分离菌的变迁及耐药性监测[J].中国感染与化疗杂志,2007,7(1):53-57. 被引量:8

二级参考文献16

共引文献19

论文智能改写系统
维普数据出版直通车
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈